RESUMEN
The metalloproteinase ADAMTS13 (a disintegrin with a thrombospondin type 1 motif, member 13), also known as VWF (von Willebrand factor) protease, may be assessed in a vast array of clinical conditions. Notably, a severe deficiency of ADAMTS13 characterizes TTP (thrombotic thrombocytopenic purpura), a rare but potentially fatal disorder associated with thrombosis due to accumulation of prothrombotic ultra-large VWF multimers. Although prompt identification/exclusion of TTP can be facilitated by rapid ADAMTS13 testing, the most commonly utilized assays are based on ELISA (enzyme linked immunosorbent assay) and require long turnaround time and have relatively limited throughput. Nevertheless, several rapid ADAMTS13 assays are now available, at least in select geographies. The current mini-review discusses these issues, as well as the potential utility of ADAMTS13 testing in a range of other conditions, including coronavirus disease 2019 (COVID-19).
Asunto(s)
Proteína ADAMTS13/sangre , COVID-19/complicaciones , Púrpura Trombocitopénica Trombótica/diagnóstico , SARS-CoV-2 , Proteína ADAMTS13/deficiencia , Proteína ADAMTS13/inmunología , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , COVID-19/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Transferencia Resonante de Energía de Fluorescencia , Humanos , Mediciones Luminiscentes , Masculino , Estudios Multicéntricos como Asunto , Preeclampsia/diagnóstico , Preeclampsia/enzimología , Valor Predictivo de las Pruebas , Embarazo , Púrpura Trombocitopénica Trombótica/sangre , Púrpura Trombocitopénica Trombótica/enzimología , Púrpura Trombocitopénica Trombótica/etiología , Proteínas Recombinantes/metabolismo , Sensibilidad y Especificidad , Enfermedades de von Willebrand/diagnóstico , Enfermedades de von Willebrand/enzimología , Factor de von Willebrand/metabolismoRESUMEN
Von Willebrand disease (VWD) is one of the most common inherited bleeding diseases caused by a qualitative or quantitative deficiency of the von Willebrand factor (FvW). FvW is a multimeric glycoprotein synthesized by megakaryocytes and endothelial cells and it is present in the subendothelial matrix, blood plasma, platelets, and endothelium. This glycoprotein plays an important role in thrombus formation by initiating platelet adhesion to sites of injury as well as platelet aggregation. The aim of this study was to evaluate the activities of enzymes that hydrolyze adenine nucleotides in platelets, ristocetin-induced platelet aggregation (RIPA), and polymorphisms of the alpha2 gene of alpha2beta1 integrin from VWD patients. Platelet nucleoside triphosphate diphosphohydrolase (NTPDase), 5'-nucleotidase, and ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) activities were verified in 14 VWD patients. For RIPA determination, a final concentration of 1.25 mg/ml of ristocetin was used. Polymorphisms of the alpha2 gene were analyzed through PCR. Platelet NTPDase and E-NPP were decreased in VWD patients. 5'-Nucleotidase activity was not statistically significant between controls and VWD patients. RIPA was significantly reduced, with an allelic frequency of 78.57% for 807C in VWD patients. Our results indicated reduced platelet NTPDase and E-NPP activities which might be related to the low platelet adhesiveness. The prevalence of the 807C allele might account for the variability in bleeding in VWD.
Asunto(s)
Nucleótidos de Adenina/sangre , Plaquetas/enzimología , Hidrolasas/sangre , Integrina alfa2/genética , Integrina alfa2beta1/genética , Polimorfismo Genético , Enfermedades de von Willebrand/enzimología , Enfermedades de von Willebrand/genética , 5'-Nucleotidasa/sangre , Adolescente , Adulto , Brasil , Estudios de Casos y Controles , Niño , Femenino , Frecuencia de los Genes , Genotipo , Hemostasis/genética , Humanos , Hidrólisis , Masculino , Nucleósido-Trifosfatasa/sangre , Tiempo de Tromboplastina Parcial , Fenotipo , Hidrolasas Diéster Fosfóricas/sangre , Agregación Plaquetaria/genética , Recuento de Plaquetas , Tiempo de Protrombina , Pirofosfatasas/sangre , Adulto Joven , Enfermedades de von Willebrand/sangreRESUMEN
Pro-thrombin activatable fibrinolysis inhibitor (pro-TAFI), also called plasma procarboxypeptidase B or U, is one of the modulators of fibrinolysis in blood. Pro-TAFI is activated by thrombin/thrombomodulin complex or by plasmin to a carboxypeptidase B-like enzyme (TAFI) of 35.8 kD molecular weight. TAFI spontaneously becomes inactive as a result of a temperature-dependent conformational change in the protein (TAFIi). In this study, pro-TAFI, total TAFI antigen and TAFI-TAFIi antigen levels were measured in 32 patients with hemophilia A, 4 patients with hemophilia B, 21 patients with von Willebrand disease (VWD) and 13 healthy controls. A statistically significant decrease in pro-TAFI was found in all groups (10.72+/-4.57 mg/L (p<0.001); 8.00+/-2.35 mg/L (p<0.01) and 8.98+/-2.33 mg/L (p <0.001) for hemophilia A, hemophilia B and VWD, respectively) compared to controls (17.85+4.61 mg/L). A statistically significant increase in TAFI-TAFIi antigen was found in hemophilia A (1.05+/-1.01 mg/L) (p<0.05) and in VWD patients (0.96+/-1.01 mg/L) (p<0.05) compared to controls (0.55+/-0.36 mg/L). There was no difference in total TAFI antigen levels between any group of patients and the controls. Neither did pro-TAFI nor TAFI-TAFIi levels differ within the group of hemophilia A patients in relation to severity (mild, moderate and severe) or among the VWD patients in relation to subtype (type 1, type 2A and type 3). These findings indicate an increased conversion of pro-TAFI to TAFI and/or TAFIi in patients with bleeding disorders. As thrombin generation is seriously impaired in these patients and almost absent in hemophilia A and B and in type 3 VWD, it is possible that plasmin mediates pro-TAFI activation in these patients. Enhanced fibrinolysis via generation of plasmin has previously been reported in hemophilia and VWD. Activation of pro-TAFI by plasmin may be a feedback mechanism that counterbalances increased fibrinolysis in patients with bleeding disorders. The relationship between the TAFI activation pathway and bleeding complications associated with hemophilia A, hemophilia B and VWD requires further investigation.
Asunto(s)
Carboxipeptidasa B2/metabolismo , Hemofilia A/enzimología , Hemofilia B/enzimología , Trombina/metabolismo , Enfermedades de von Willebrand/enzimología , Adulto , Anciano , Antígenos/inmunología , Antígenos/metabolismo , Carboxipeptidasa B2/inmunología , Femenino , Fibrinólisis , Hemofilia A/inmunología , Hemofilia A/metabolismo , Hemofilia B/inmunología , Hemofilia B/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/metabolismoRESUMEN
von Willebrand factor-cleaving protease (ADAMTS13) cleaves von Willebrand factor (VWF) and regulates its physiologic function. To investigate the relation between ADAMTS13 activity and VWF, we compared ADAMTS13 activity with the VWF-related parameters VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CBA), VWF-propeptide, proVWF, and VWF multimeric composition in 10 healthy volunteers and 3 patients with type 1 von Willebrand disease before and after infusing 0.3 microg/kg desmopressin. The VWF-related parameters in the volunteers increased 60 minutes after start of infusion by 3.7-fold for VWF:Ag, 7.2-fold for propeptide, and 2.2-fold for VWF:CBA. Unusually large VWF multimers and traces of proVWF appeared. The ADAMTS13 activity decreased to about half the initial value. After 24 hours values returned to baseline. Patients with type 1 von Willebrand disease showed similar results. We conclude that the inverse correlation between ADAMTS13 and VWF-related parameters suggests a consumption of ADAMTS13 after the desmopressin-induced release of higher multimers of VWF.
Asunto(s)
Desamino Arginina Vasopresina/farmacología , Metaloendopeptidasas/efectos de los fármacos , Proteínas ADAM , Proteína ADAMTS13 , Adulto , Estudios de Casos y Controles , Colágeno/metabolismo , Desamino Arginina Vasopresina/administración & dosificación , Dimerización , Femenino , Humanos , Infusiones Parenterales , Masculino , Metaloendopeptidasas/metabolismo , Persona de Mediana Edad , Enfermedades de von Willebrand/tratamiento farmacológico , Enfermedades de von Willebrand/enzimología , Factor de von Willebrand/efectos de los fármacos , Factor de von Willebrand/metabolismoRESUMEN
Low levels of von Willebrand factor (VWF) in von Willebrand's disease type 2A (VWD 2A) result from increased cleavage of the bond 842Tyr-843Met in the VWF protein by VWF cleaving protease. On the other hand, decreased levels of this protease result in unusually large VWF in thrombotic thrombcytopenic purpura with thrombotic complications. In the present study, we designed an enzyme-liked immunosorbent assay of VWF cleaving protease activity to be used to assess whether the high levels of VWF in coronary heart disease (CHD) relate to a deficiency of this protease. Plasma samples with added Pefabloc and CaCl(2) were incubated with purified VWF coated on a microtiter plate. The remaining undigested multimers were quantified by an antibody directed against the intact 842Tyr-843Met bond of the VWF protein. Phosphate-buffered saline (PBS), instead of plasma, was used to obtain the initial level of coated undigested VWF. The reduction in absorbance at 492 nm between PBS and the unknown sample was taken as a measure of the protease activity. The assay was applied to plasma samples from 21 senior women with chronic CHD (cases) and 34 age-matched controls, as well as to samples from three patients with VWD 2A. The protease activity was similar in the two women groups (P>.05), although the VWF antigen levels were higher in the cases (P<.01). The VWD 2A patients had similar plasma levels of the protease to that in normal pooled plasma (NPP). In the senior controls, the protease activity correlated with the subject age (r's=-.61, P<.01, n=34). In conclusion, the developed method is specific for evaluating the protease function on VWF cleavage. The moderate increase of VWF antigen in chronic CHD may not depend on the protease activity. The age influence on the protease levels supports earlier findings of higher VWF levels in healthy older subjects. A high sensitivity of the mutated protein of VWF for the protease effect rather than increases in activity or quantity of the enzyme is probably involved in the pathogenesis of VWD 2A.
Asunto(s)
Enfermedad Coronaria/sangre , Metaloendopeptidasas/sangre , Factor de von Willebrand/metabolismo , Sistema del Grupo Sanguíneo ABO , Proteínas ADAM , Proteína ADAMTS13 , Anciano , Anticuerpos Monoclonales , Sitios de Unión , Estudios de Casos y Controles , Enfermedad Crónica , Enfermedad Coronaria/enzimología , Enfermedad Coronaria/etiología , Ensayo de Inmunoadsorción Enzimática/normas , Femenino , Humanos , Metaloendopeptidasas/metabolismo , Metaloendopeptidasas/farmacología , Persona de Mediana Edad , Enfermedades de von Willebrand/sangre , Enfermedades de von Willebrand/enzimología , Enfermedades de von Willebrand/etiología , Factor de von Willebrand/efectos de los fármacos , Factor de von Willebrand/inmunologíaRESUMEN
Previous observations on the heterogeneous distribution of von Willebrand factor in the vascular endothelium led us to examine the expression of angiotensin I-converting enzyme (ACE) in function of the vascular origin of endothelial cells (EC). EC from pig thoracic aorta, pulmonary artery, inferior vena cava and brain capillaries were cultured and assayed for ACE by enzymatic radiochemical determination and by western-blot and immunofluorescence using an antiACE polyclonal antibody. EC from the various vascular levels secreted ACE in the culture medium; western-blot analysis showed its presence at cellular level and immunofluorescence confirmed its location on the plasma membrane. But quantification revealed that EC from pulmonary artery contain more ACE than EC from the other vessels, especially from brain capillaries; immunofluorescence correlated well with the functional data. In contrast, secretion of ACE by brain capillaries EC was faster than that of arteries and of vena cava, the latter being the less effective. This differential ACE expression along the vascular tree could have a pharmacological implication since ACE inhibitors, used in the treatment of arterial hypertension, may act more at the vascular level than on the plasma renin-angiotensin system. On the other hand, endothelial distribution of ACE was different from that of von Willebrand factor; in particular we showed that EC cultured from vessels of pigs homozygous for the von Willebrand disease, in which von Willebrand factor synthesis was completely abolished, normally express ACE.
Asunto(s)
Endotelio Vascular/enzimología , Peptidil-Dipeptidasa A/análisis , Animales , Aorta Torácica , Encéfalo/irrigación sanguínea , Capilares , Membrana Celular/enzimología , Células Cultivadas , Peptidil-Dipeptidasa A/metabolismo , Arteria Pulmonar , Porcinos , Vena Cava Inferior , Enfermedades de von Willebrand/enzimologíaRESUMEN
Patients with histories of bleeding disorders may still benefit from regional anesthetic techniques. The decision to perform the block should be individualized, based on coagulation tests. The authors describe a patient with von Willebrand's disease in whom pregnancy itself improved factor VIII activity, enabling performance of an epidural block for labor and delivery.